Research

C.U.P.

Centro Unico Prenotazioni
Ospedale San Camillo IRCCS
Lido di Venezia

Tel. 041 2207244

Numero Verde 800 862434

(Lun-Ven dalle 11.00 alle 14.00)

Centralino

Tel. 041 2207111


Clicca qui per accedere al portale dovesalute.gov.it del Ministero della Salute


5x1000_SanCamillo.gif


iscriviti-newsletter.gif


Dati Fiscali

C.F.: 94071440278

P.I.: 03953700279

Cod. Fatt. Elettronica: MVRC5PM

Sede legale: Via Alberoni, 70,

30126 Lido di Venezia

Line 1

Neurobiological premises of functional recovery

Research line 1
"Neurobiological premises of functional recovery"
Scientific Responsible
Corrado Angelini

Prof. Corrado Angelini
, neurologist
e-mail: corrado.angelini@ospedalesancamillo.net
Twitter: @AngeliniCorrado
Staff assigned
Dr. Laura Giaretta Biotechnologist with PhD in biotechnology
  Dr. Roberta Marozzo Biologist
  Dr. Valentina Pegoraro Biotechnologist with PhD in Clinical and
Experimental Medical Science, address Neuroscience
Collaborators Dr. Alfonc Baba Physical therapist - Twitter: @AlfoncBaba
  Dr. Francesca Bevilacqua Psychologist - Curriculum Vitae
Twitter: @FranBevi73
  Dr. Paola Cudia Curriculum Vitae
  Dr. Antonio Merico Curriculum Vitae
Resp. S.S. Amyotrophic Lateral Sclerosis
Resp. S. of Clinical Neurophysiology

Twitter: @merico4s
  Mrs. Elena Pazienza Laboratory technical assistant
  Dr. Elena Pinzan Psychologist

 

Description of the Research line

Research projects belonging to Line 1 "Neurobiological premises of functional recovery" are aimed at understanding the pathophysiological and genetic basis involved in multiple and severe neurological, rare, neurodegenerative, cerebro-vascular, post-traumatic and neuromuscular diseases. This line is engaged in the research in the field of proteomics and genomics to identify the factors of susceptibility to neurological, neuromuscular and rare as well as in the identification of new markers of prognostic, diagnostic and therapeutic significance.

 

Technologies

The different research areas use the most advanced genomic and post-genomic technologies (miRNA, cDNA, protein mutations analysis and Western Blot), innovative technologies in the field of cell biology (eg. iPSc), biochemistry, cytochemistry. Translational studies are performed on biological samples (serum, plasma, etc.) and cell cultures based on fibroblasts and peripheral blood obtained from patients in rehabilitation treatment at IRCCS San Camillo.

 

Goals

The main goals of Research line 1 are to clarify the mechanisms underlying some fundamental neurobiological processes, including cell death, necrosis, repairing, regeneration and neuronal plasticity and muscular, learning and oxidative damage. Neurobiological results will serve to identify new specific clinical/diagnostic and therapeutic rehabilitation paths for patients with different pathologies of central, peripheral and muscular nervous system. The aim is to identify the rational bases for possible new therapeutic approaches that facilitate recovery mechanisms; provide biological indicators to understand better the basics of clinical variability in patients and facilitate the prognosis of outcome in neurorehabilitation.

The results obtained will find their way in new clinical/diagnostic routes and integrated - and, as such, more complete - rehabilitation therapies for the treatment of patients.

 

Representative projects

  • Role of atrophy and autophagy in neuromuscular diseases and correlation of muscle atrophy through imaging.
  • Rare diseases BioBank and Neurorehabilitation – BBMRNR
  • Molecular effects of rehabilitation treatment in Myotonic Dystrophy type I: analysis of serum microRNAs
  • Evaluation of serum specific muscle microRNA alterations in ALS patients undergoing rehabilitation treatment
  • Changes in biochemical markers determined by therapeutic rehabilitation intervention in patients with ALS
  • Muscular cultures as a functional neuromuscular damage model, mitochondrial disorders, rare metabolic diseases
  • Evaluation of the effects of rehabilitation treatment in Muscular Dystrophies using MRI of skeletal muscle

The Research line 1 participated in 2015 and 2016 Capital Account project promoted by the Ministry of Health to create a network of excellence for the study of biomarkers, advanced molecular and care characterization of neuromuscular and neurodegenerative diseases.

There are also two active Telethon projects:

  • Clinical and molecular characterization of FSHD families as a prerequisite to assess the effectiveness of therapies (GUP13013)
  • Study of pathogenetic and clinical aspects of Neutral Lipid Storage Syndromes (NLSD) (GGP14066)

 

Most relevant publications:

  1. Angelini, C., Nascimbeni, A.C., Cenacchi, G., Tasca, E.
    Lipolysis and lipophagy in lipid storage myopathies
    (2016) Biochimica et Biophysica Acta - Molecular Basis of Disease, 1862 (7), pp. 1367-1373.
    DOI: 10.1016/j.bbadis.2016.04.008
     
  2. Angelini, C., Savarese, M., Fanin, M., Nigro, V.
    Next generation sequencing detection of late onset pompe disease
    (2016) Muscle and Nerve, 53 (6), pp. 981-983.
    DOI: 10.1002/mus.25042
     
  3. Giugliano, T., Fanin, M., Savarese, M., Piluso, G., Angelini, C., Nigro, V.
    Identification of an intragenic deletion in the SGCB gene through a re-evaluation of negative next generation sequencing results
    (2016) Neuromuscular Disorders, 26 (6), pp. 367-369.
    DOI: 10.1016/j.nmd.2016.02.013
     
  4. Ricci, G., Ruggiero, L., Vercelli, L., Sera, F., Nikolic, A., Govi, M., Mele, F., Daolio, J., Angelini, C., Antonini, G., Berardinelli, A., Bucci, E., Cao, M., D’Amico, M.C., D’Angelo, G., Di Muzio, A., Filosto, M., Maggi, L., Moggio, M., Mongini, T., Morandi, L., Pegoraro, E., Rodolico, C., Santoro, L., Siciliano, G., Tomelleri, G., Villa, L., Tupler, R.
    A novel clinical tool to classify facioscapulohumeral muscular dystrophy phenotypes
    (2016) Journal of Neurology, pp. 1-11. Article in Press.
    DOI: 10.1007/s00415-016-8123-2
     
  5. Cudia, P., Weis, L., Baba, A., Kiper, P., Marcante, A., Rossi, S., Angelini, C., Piccione, F.
    Effects of Functional Electrical Stimulation Lower Extremity Training in Myotonic Dystrophy Type I: A Pilot Controlled Study
    (2016) Am J Phys Med Rehabil. 95(11), pp. 809-817.
    DOI:10.1097/PHM.0000000000000497
     
  6. Angelini, C.
    Challenges and progress in the diagnosis of Congenital Muscular Dystrophies
    (2016) Expert Opinion on Orphan Drugs, 4 (4), pp. 347-358.
    DOI: 10.1517/21678707.2016.1145587
    Document type: Review
     
  7. Mancuso, M., Orsucci, D., Angelini, C., Bertini, E., Carelli, V., Comi, G.P., Federico, A., Minetti, C., Moggio, M., Mongini, T., Tonin, P., Toscano, A., Bruno, C., Ienco, E.C., Filosto, M., Lamperti, C., Diodato, D., Moroni, I., Musumeci, O., Pegoraro, E., Spinazzi, M., Ahmed, N., Sciacco, M., Vercelli, L., Ardissone, A., Zeviani, M., Siciliano, G.
    "Mitochondrial neuropathies": A survey from the large cohort of the Italian Network
    (2016) Neuromuscular Disorders, 26 (4-5), pp. 272-276.
    DOI: 10.1016/j.nmd.2016.02.008
     
  8. Angelini, C.
    Neuromuscular disease: Diagnosis and discovery in limb-girdle muscular dystrophy
    (2016) Nature Reviews Neurology, 12 (1), pp. 6-8.
    DOI: 10.1038/nrneurol.2015.230
    Document type: Short Survey
     
  9. Fanin, M., Nigro, V., Angelini, C.
    Reply
    (2016) Muscle and Nerve, 53 (1), pp. 157-158.
    DOI: 10.1002/mus.24898
    Document type: Letter
     
  10. Tasca, E., Pegoraro, V., Merico, A., Angelini, C.
    Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS
    (2016) Clinical Neuropathology, 35 (1), pp. 22-30.
    DOI: 10.5414/NP300889
     
  11. Musumeci, O., Marca, G.L., Spada, M., Mondello, S., Danesino, C., Comi, G.P., Pegoraro, E., Antonini, G., Marrosu, G., Liguori, R., Morandi, L., Moggio, M., Massa, R., Ravaglia, S., Muzio, A.D., Filosto, M., Tonin, P., Iorio, G.D., Servidei, S., Siciliano, G., Angelini, C., Mongini, T., Toscano, A.
    LOPED study: Looking for an early diagnosis in a late-onset Pompe disease high-risk population
    (2016) Journal of Neurology, Neurosurgery and Psychiatry, 87 (1), pp. 5-11.
    DOI: 10.1136/jnnp-2014-310164
     
  12. Magri F, Nigro V, Angelini C, Mongini T, Mora M, Moroni I, Toscano A, D'angelo MG, Tomelleri G, Siciliano G, Ricci G, Bruno C, Corti S, Musumeci O, Tasca G, Ricci E, Monforte M, Sciacco M, Fiorillo C, Gandossini S, Minetti C, Morandi L, Savarese M, Fruscio GD, Semplicini C, Pegoraro E, Govoni A, Brusa R, Del Bo R, Ronchi D, Moggio M, Bresolin N, Comi GP.
    The italian limb girdle muscular dystrophy registry: Relative frequency, clinical features, and differential diagnosis.
    (2016) Muscle Nerve. [Epub ahead of print]
    DOI:10.1002/mus.25192.
     
  13. Fanin M, Angelini C.
    Progress and challenges in diagnosis of dysferlinopathy.
    (2016) Muscle Nerve, 54(5): pp.821-835.
    DOI: 10.1002/mus.25367.
     
  14. Bello L, Campadello P, Barp A, Fanin M, Semplicini C, Sorarù G, Caumo L, Calore C, Angelini C, Pegoraro E.
    Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathies.
    (2016) Sci Rep, 6: pp. 32439.
    DOI: 10.1038/srep32439.
     
  15. Aguennouz M, Lo Giudice C, Licata N, Rodolico C, Musumeci O, Fanin M, Migliorato A, Ragusa M, Macaione V, Di Giorgio RM, Angelini C, Toscano A.
    MicroRNA signatures predict dysregulated vitamin D receptor and calcium pathways status in limb girdle muscle dystrophies (LGMD) 2A/2B.
    (2016) Cell Biochem Funct. 34(6): pp.414-22.
    DOI: 10.1002/cbf.3202.
     
  16. Baldanzi S, Cecchi P, Fabbri S, Pesaresi I, Simoncini C, Angelini C, Bonuccelli U, Cosottini M, Siciliano G
    Relationship between neuropsychological impairment and grey and white matter changes in adult-onset myotonic dystrophy type 1.
    (2016) Neuroimage Clin.,12 : pp.190-7.
    DOI: 10.1016/j.nicl.2016.06.011
     
  17. Savarese M, Di Fruscio G, Torella A, Fiorillo C, Magri F, Fanin M, Ruggiero L, Ricci G, Astrea G, Passamano L, Ruggieri A, Ronchi D, Tasca G, D'Amico A, Janssens S, Farina O, Mutarelli M, Marwah VS, Garofalo A, Giugliano T, Sanpaolo S, Del Vecchio Blanco F, Esposito G, Piluso G, D'Ambrosio P, Petillo R, Musumeci O, Rodolico C, Messina S, Evilä A, Hackman P, Filosto M, Di Iorio G, Siciliano G, Mora M, Maggi L, Minetti C, Sacconi S, Santoro L, Claes K, Vercelli L, Mongini T, Ricci E, Gualandi F, Tupler R, De Bleecker J, Udd B, Toscano A, Moggio M, Pegoraro E, Bertini E, Mercuri E, Angelini C, Santorelli FM, Politano L, Bruno C, Comi GP, Nigro V.
    The genetic basis of undiagnosed muscular dystrophies and myopathies: Results from 504 patients.
    (2016) Neurology, 87(1): pp. 71-6.
    DOI: 10.1212/WNL.0000000000002800.
     
  18. Baldanzi S, Bevilacqua F, Lorio R, Volpi L, Simoncini C, Petrucci A, Cosottini M, Massimetti G, Tognoni G, Ricci G, Angelini C, Siciliano G.
    Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study.
    (2016) Orphanet J Rare Dis, 11 (34).
    DOI:10.1186/s13023-016-0417-z.

 Last update: January 2018

Numeri utili I.R.C.C.S. Ospedale San Camillo di Venezia

Come raggiungerci

  • Da Venezia P.Roma / Stazione FS

    linee di navigazione n° 1 - 5.1 - 6
  • Da Lido S.Maria Elisabetta:

    linee autobus A direzione Alberoni.
  • Da Venezia Tronchetto:

    Linea 17 (ferry-boat) per Lido.
  • Da Chioggia:

    Linea 11 per Lido.

Da Aeroporto Marco Polo:

Da Fusina:

 

Come raggiungere il SAN CAMILLO

 

 

Dati Fiscali: C.F.: 94071440278 - P.I.: 03953700279 - Cod. Fatt. Elettronica: MVRC5PM - Sede legale: Via Alberoni, 70, 30126 Lido di Venezia